SCHEMBL15919295

SCHEMBL15919295

CC(C)CN(C(=O)c1ccc(C#Cc2ccc(-c3cc(C(=O)NN)c4cnccc4n3)cc2)cc1)C(CO)C(=O)O

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.37
▸ LMNA P02545 3/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ GAA P10253 2/20 0.37
▸ P4HB P07237 1/20 0.37
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ RAD52 P43351 1/20 0.35
▸ UBE2N P61088 1/20 0.35
▸ CYP3A4 P08684 3/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ DHODH Q02127 1/20 0.34
▸ LATS1 O95835 1/20 0.34
▸ TACR3 P29371 1/20 0.34
▸ MAPK1 P28482 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ TP53 P04637 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15919465 0.94 LATS1 (0.38) MAPTLMNAALDH1A1GAAP4HB
SCHEMBL15904951 0.92 KMT2A (0.33) MAPTLMNAALDH1A1GAAP4HB
SCHEMBL15919654 0.91 MAPT (0.38) MAPTLMNAALDH1A1GAAP4HB
SCHEMBL15919650 0.91 MAPT (0.39) MAPTALDH1A1GAAMEN1KMT2A
SCHEMBL15919641 0.90 MAPT (0.41) MAPTLMNAALDH1A1GAAP4HB
SCHEMBL15919460 0.88 ACACB (0.39) MAPTGAAMEN1KMT2ALATS1
SCHEMBL17327512 0.86 LATS1 (0.36) MAPTLMNAMEN1KMT2ARAD52
SCHEMBL15919610 0.86 LATS1 (0.34) MAPTLMNAALDH1A1GAAP4HB
SCHEMBL15905087 0.86 LATS1 (0.34) MAPTLMNAALDH1A1GAAP4HB
SCHEMBL15919561 0.86 MAPT (0.38) MAPTLMNAALDH1A1GAAP4HB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS Viamet Pharmaceuticals (NC), Inc. 2015-12-10 — — US claimed
US-9663488-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2017-05-30 — — US disclosed
US-9663488-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2017-05-30 — — US disclosed
US-9663488-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2017-05-30 — — US disclosed
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS Viamet Pharmaceuticals (NC), Inc. 2015-12-10 — — US disclosed
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS Viamet Pharmaceuticals (NC), Inc. 2015-12-10 — — US disclosed
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS Viamet Pharmaceuticals (NC), Inc. 2015-12-10 — — US disclosed
WO-2014117090-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2014-07-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO MAPT 2507/4885LMNA 4266/4885ALDH1A1 289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback